Logo

Compugen Announces Addition of Two Proteins to Pipeline

Jun 07, 2004

NEW YORK, June 7 (GenomeWeb News) - Compugen said today that it has recently added two novel therapeutic proteins, identified using the company's discovery engines, to its research pipeline.

 

According to the company, the proteins are CGEN M-3, a soluble kinase receptor with potential applications in cancer, and CGEN P-4, a peptide that may be useful in the areas of obesity and eating disorders.

 

The proteins, said Compugen, were initially predicted in-silico and are now being evaluated in the company's molecular biology labs.

 

Breaking News
The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.